Currie Mark G 4
4 · IRONWOOD PHARMACEUTICALS INC · Filed Jan 24, 2020
Insider Transaction Report
Form 4
Currie Mark G
Chief Scientific Officer
Transactions
- Sale
Class A Common Stock
2020-01-23$12.59/sh−60,000$755,400→ 549,272 total - Exercise/Conversion
Class A Common Stock
2020-01-23$9.12/sh+60,000$547,200→ 609,272 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2020-01-23−60,000→ 47,707 totalExercise: $9.12Exp: 2026-03-01→ Class A Common Stock (60,000 underlying)
Footnotes (3)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The option, granted as an annual performance award, is presently exercisable in full.